2021年5月11日
Utility of remission criteria for the renal prognosis of IgA nephropathy
Clinical and Experimental Nephrology
- ,
- ,
- ,
- ,
- 巻
- 25
- 号
- 9
- 開始ページ
- 988
- 終了ページ
- 995
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1007/s10157-021-02069-w
- 出版者・発行元
- Springer Science and Business Media LLC
<title>Abstract</title><sec>
<title>Background</title>
Novel criteria for the remission of Immunoglobulin A nephropathy (IgAN) based on an opinion survey of Japanese nephrologists and literature review were proposed in 2013. This single-center, longitudinal retrospective cohort study was conducted to validate this criteria.
</sec><sec>
<title>Methods</title>
Present study included the IgAN patients diagnosed between 2001 and 2005 in the Juntendo University Hospital. Remission of hematuria was defined as three consecutive dipstick test results of ( −) to ( ±) or a red blood cell count < 5 in urinary sediment per high-power field during at least 6 months. Remission of proteinuria was defined as three consecutive dipstick results of ( −) to ( ±) during at least 6 months. We categorized four groups according to the remission status which was assessed 2 years after the renal biopsy. The primary outcome was a 50% increase in the serum creatinine over the baseline. We evaluated the slope of eGFR decline (mL/min/1.73 m2/year) and a decrease in the eGFR of 30% from baseline eGFR as the secondary outcome, respectively.
</sec><sec>
<title>Results</title>
A total of 74 patients (male: 47.3%, median age: 30 years) were included and were followed for a median of 86.5 months. During the period, forty-one patients achieved neither remission of proteinuria nor hematuria (NR). Twelve patients met the primary study outcome. A survival analysis revealed that the NR had the worst prognosis and the steepest slope of eGFR decline.
</sec><sec>
<title>Conclusion</title>
Although further validation in a large cohort is necessary, these novel remission criteria for IgAN patients appear to predict the renal prognosis.
</sec>
<title>Background</title>
Novel criteria for the remission of Immunoglobulin A nephropathy (IgAN) based on an opinion survey of Japanese nephrologists and literature review were proposed in 2013. This single-center, longitudinal retrospective cohort study was conducted to validate this criteria.
</sec><sec>
<title>Methods</title>
Present study included the IgAN patients diagnosed between 2001 and 2005 in the Juntendo University Hospital. Remission of hematuria was defined as three consecutive dipstick test results of ( −) to ( ±) or a red blood cell count < 5 in urinary sediment per high-power field during at least 6 months. Remission of proteinuria was defined as three consecutive dipstick results of ( −) to ( ±) during at least 6 months. We categorized four groups according to the remission status which was assessed 2 years after the renal biopsy. The primary outcome was a 50% increase in the serum creatinine over the baseline. We evaluated the slope of eGFR decline (mL/min/1.73 m2/year) and a decrease in the eGFR of 30% from baseline eGFR as the secondary outcome, respectively.
</sec><sec>
<title>Results</title>
A total of 74 patients (male: 47.3%, median age: 30 years) were included and were followed for a median of 86.5 months. During the period, forty-one patients achieved neither remission of proteinuria nor hematuria (NR). Twelve patients met the primary study outcome. A survival analysis revealed that the NR had the worst prognosis and the steepest slope of eGFR decline.
</sec><sec>
<title>Conclusion</title>
Although further validation in a large cohort is necessary, these novel remission criteria for IgAN patients appear to predict the renal prognosis.
</sec>
- リンク情報
-
- DOI
- https://doi.org/10.1007/s10157-021-02069-w
- PubMed
- https://www.ncbi.nlm.nih.gov/pubmed/33974158
- PubMed Central
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357773
- 共同研究・競争的資金等の研究課題
- 標準化された項目を用いた統合型IgA腎症データベースの構築に向けた研究
- URL
- https://link.springer.com/content/pdf/10.1007/s10157-021-02069-w.pdf
- URL
- https://link.springer.com/article/10.1007/s10157-021-02069-w/fulltext.html
- ID情報
-
- DOI : 10.1007/s10157-021-02069-w
- ISSN : 1342-1751
- eISSN : 1437-7799
- PubMed ID : 33974158
- PubMed Central 記事ID : PMC8357773